sunitinib
pfizer
['pancreatic', 'sunitinib']
 prrt vs sunitinib in advanced pancreatic neuroendocrine tumor at #esmo22 84 pretreated pts 1 endpoint: 12m-pfs rate sunitinib: 42% -&gt; mpfs 11 mo lu-dotate: 80% -&gt; mpfs 20.7 mo positive trial -&gt; practice changing? 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine